TC
STRO icon

Tejara Capital’s Sutro Biopharma STRO Stock Holding History

Tejara Capital’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,315
Closed -$595K – 72
2024
Q2 		$595K Buy
20,315
+873
+4% +$34.5K 0.22% 56
2024
Q1 		$1.1M Sell
19,442
-3,253
-14% -$144K 0.4% 45
2023
Q4 		$974K Buy
22,695
+13,827
+156% +$439K 0.41% 46
2023
Q3 		$308K Hold
8,868
– – 0.17% 60
2023
Q2 		$412K Buy
8,868
+4,420
+99% +$220K 0.2% 62
2023
Q1 		$206K Buy
+4,448
New +$282K 0.11% 77

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital's STRO Position: Q3 2024 in Review

Tejara Capital sold out of Sutro Biopharma (STRO) in Q3 2024, closing a stake of 20,315 shares — an estimated $595K sold.

Tejara Capital first reported a position in STRO in Q1 2023 and held it in 6 quarters. The position peaked at $1.1M in Q1 2024. 130 funds tracked by Wall St. Rank hold STRO as of Q3 2024.

  • Tejara Capital reported no remaining Sutro Biopharma position as of Q3 2024 after selling out during the quarter.
  • Tejara Capital sold 20,315 Sutro Biopharma shares in Q3 2024, an estimated $595K.
  • Tejara Capital first reported a position in Sutro Biopharma in Q1 2023 and held it in 6 quarters.
  • Tejara Capital's Sutro Biopharma position peaked at $1.1M in Q1 2024.
  • 130 funds tracked by Wall St. Rank held Sutro Biopharma as of Q3 2024.

Based on Tejara Capital's 13F filing for Q3 2024, filed 13 Nov 2024.